Safety of the combination of lapatinib (L) plus trastuzumab (T) in patients (pts) with HER2-Positive (+) metastatic breast cancer (MBC)

被引：0
|
作者：
Storniolo, A. [1 ]
Koehler, M. [2 ]
Preston, A. [2 ]
Rappold, E. [2 ]
Byrne, J. [2 ]
Stein, S. [2 ]
Ewer, M. [3 ]
机构：
[1] Indiana Univ, Med Ctr, Indianapolis, IN USA
[2] GlaxoSmithKline Inc, Oncol Med Dev Ctr, Collegeville, PA USA
[3] MD Anderson Canc Ctr, Houston, TX USA
来源：
EJC SUPPLEMENTS | 2007年 / 5卷 / 04期
关键词：
D O I：
10.1016/S1359-6349(07)70771-1
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：187 / 187
页数：1
相关论文
共 50 条
  • [21] Efficacy and safety of trastuzumab plus capecitabine in heavily pretreated patients with HER2-positive metastatic breast cancer
    Osako, Tomo
    Ito, Yoshinori
    Takahashi, Shunji
    Tokudome, Nahomi
    Iwase, Takuji
    Hatake, Kiyohiko
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2008, 62 (01) : 159 - 164
  • [22] Efficacy and safety of trastuzumab plus capecitabine in heavily pretreated patients with HER2-positive metastatic breast cancer
    Tomo Osako
    Yoshinori Ito
    Shunji Takahashi
    Nahomi Tokudome
    Takuji Iwase
    Kiyohiko Hatake
    Cancer Chemotherapy and Pharmacology, 2008, 62 : 159 - 164
  • [23] Efficacy and safety of the combination of lapatinib plus capecitabine for HER2-positive advanced breast cancer.
    Aravantino-Fatorou, E.
    Christodoulou, C.
    Nikolakopoulou, A.
    Galani, E.
    Klouvas, G.
    Acholos, V.
    Karapanagiotidis, G.
    Batziou, E.
    Tsakalos, G.
    Skarlos, D.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [24] A retrospective, multicenter study of the efficacy of lapatinib plus trastuzumab in HER2-positive metastatic breast cancer patients previously treated with trastuzumab, lapatinib, or both: the Trastyvere study
    Gavila, J.
    De La Haba, J.
    Bermejo, B.
    Rodriguez-Lescure, A.
    Anton, A.
    Ciruelos, E.
    Brunet, J.
    Munoz-Couselo, E.
    Santisteban, M.
    Rodriguez Sanchez, C. A.
    Santaballa, A.
    Sanchez Rovira, P.
    Garcia Saenz, J. a.
    Ruiz-Borrego, M.
    Guerrero-Zotano, A. L.
    Huerta, M.
    Cotes-Sanchis, A.
    Lao Romera, J.
    Aguirre, E.
    Cortes, J.
    Llombart-Cussac, A.
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2020, 22 (03): : 420 - 428
  • [25] A retrospective, multicenter study of the efficacy of lapatinib plus trastuzumab in HER2-positive metastatic breast cancer patients previously treated with trastuzumab, lapatinib, or both: the Trastyvere study
    J. Gavilá
    J. De La Haba
    B. Bermejo
    Á. Rodríguez-Lescure
    A. Antón
    E. Ciruelos
    J. Brunet
    E. Muñoz-Couselo
    M. Santisteban
    C. A. Rodríguez Sánchez
    A. Santaballa
    P. Sánchez Rovira
    J. Á. García Sáenz
    M. Ruiz-Borrego
    A. L. Guerrero-Zotano
    M. Huerta
    A. Cotes-Sanchís
    J. Lao Romera
    E. Aguirre
    J. Cortés
    A. Llombart-Cussac
    Clinical and Translational Oncology, 2020, 22 : 420 - 428
  • [26] Outcome of HER2-Positive (HER2+) Metastatic Breast Cancer Patients (MBC) Treated with Trastuzumab (T): An Institutional Based Review
    Guilhaume, M-N
    Dieras, V
    Fall, M.
    Pierga, J-Y
    Beuzeboc, P.
    Cottu, P. H.
    Simondi, C.
    Courbard, M.
    Mignot, L.
    Livartowski, A.
    CANCER RESEARCH, 2009, 69 (24) : 801S - 801S
  • [27] Tolerability of the combination of lapatinib and trastuzumab in older patients with HER2 positive metastatic breast cancer
    O'Connor, Tracey
    Soto-Perez-de-Celis, Enrique
    Blanchard, Suzette
    Chapman, Andrew
    Kimmick, Gretchen
    Muss, Hyman
    Luu, Thehang
    Waisman, James R.
    Li, Daneng
    Mortimer, Joanne
    Yuan, Yuan
    Somlo, George
    Stewart, Daphne
    Katheria, Vani
    Levi, Abrahm
    Hurria, Arti
    CANCER RESEARCH, 2018, 78 (04)
  • [28] An Open-Label Safety Study of Lapatinib Plus Trastuzumab Plus Paclitaxel in First-Line HER2-Positive Metastatic Breast Cancer
    Esteva, Francisco J.
    Franco, Sandra X.
    Hagan, Maura K.
    Brewster, Abenaa M.
    Somer, Robert A.
    Williams, Will
    Florance, Allison M.
    Turner, Simon
    Stein, Steven
    Perez, Alejandra
    ONCOLOGIST, 2013, 18 (06): : 661 - 666
  • [29] Optimally tolerated dose of lapatinib in combination with docetaxel plus trastuzumab in first-line treatment of HER2-positive metastatic breast cancer
    Crown, J.
    Kennedy, M. J.
    Tresca, P.
    Marty, M.
    Espie, M.
    Burris, H. A.
    DeSilvio, M.
    Lau, M. R.
    Kothari, D.
    Koch, K. M.
    Dieras, V.
    ANNALS OF ONCOLOGY, 2013, 24 (08) : 2005 - 2011
  • [30] Vinflunine in combination with trastuzumab for treatment of HER2-positive metastatic breast cancer
    Paridaens, R., Sr.
    Wildiers, H.
    Dalenc, F.
    Rixe, O.
    Cadic, V.
    Pinel, M.
    Roche, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
12345